Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
Open Access
- 22 December 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 268 (5) , 1728-1737
Abstract
Objectives: Levodopa–Carbidopa Intrajejunal gel (LCIG) infusion is an effective intervention for people with advanced Parkinson’s disease (PD). Although age may not be a limiting factor for LCIG implant, no data are available on late elderly PD (LE-PD) subjects. In this cross-sectional, we aimed to demonstrate if older age may impact on quality of life (QoL), motor and non-motor symptoms severity, and profile of side effects in PD treated with LCIG. Methods: Out of 512 PD subjects treated with LCIG at 9 Italian PD centers, we selected 25 LE-PD defined as age ≥ 80 years at last follow-up who were available to attend the study visit. Twenty-five PD patients (Control-PD, defined as age < 75 years at last follow-up) matched to LE-PD by disease and LCIG duration served as control group. The following motor and non-motor variables were ascertained: quality of life (PDQ-8), time spent in ON, wearing-off Questionnaire, Unified PD Rating Scale, freezing of gait questionnaire, Parkinson’s disease sleep scale-2, Non Motor Symptoms Scale (NMSS), and MOCA. Results: No statistically significant differences were found between LE-PD and Control-PD on PDQ-8 and several motor and non-motor variables. LE-PD had less frequent and milder impulsive–compulsive behaviors and milder dyskinesia. At multivariable regression, worse quality of life was associated with UPDRS-III and NMSS scores but not to age at study visit and age at LICG implant. Rate of adverse effects was similar in both groups. Drop-out rate calculated in the whole PD cohort was comparable between the two groups. Conclusion: Our data provide evidence that valuable LCIG infusion might be achieved in late elderly PD.Keywords
Funding Information
- St. George's University of London
This publication has 28 references indexed in Scilit:
- Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving conceptsAnnals of Neurology, 2018
- Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approachCurrent Medical Research and Opinion, 2018
- Age/Disease Duration Influence on Activities of Daily Living and Quality of Life After Levodopa-Carbidopa Intestinal Gel in Parkinson’s DiseaseNeurodegenerative Disease Management, 2018
- Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s diseaseJournal of Neurology, 2018
- Sleep and REM sleep behaviour disorder in Parkinson’s disease with impulse control disorderJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Do patients with late-stage Parkinson's disease still respond to levodopa?Parkinsonism & Related Disorders, 2016
- Characteristic features of cognitive, affective and daily living functions of late‐elderly dementiaGeriatrics & Gerontology International, 2015
- Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson diseaseNeurology, 2015
- Late-stage Parkinson’s disease: the Barcelona and Lisbon cohortJournal of Neurology, 2010
- Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?Neurology, 2007